Novartis AG Common Stock (NVS)

Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ( Profile ) is determined working to change that outcome. The company is developing Lucid-MS, a patented, first-in-class drug candidate that approaches the disease from an entirely different angle by directly targeting the myelin sheath that MS destroys; the potential treatment is now preparing to move into phase 2 clinical trials. Quantum BioPharma stands among a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, a group that also includes Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and…

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

International stocks are trading for a steep discount, and here's a great way to invest.

AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (profile) is determined working to change that outcome. The company is developing Lucid-MS, a patented, first-in-class drug candidate that approaches the disease from an entirely different angle by directly targeting the myelin sheath that MS destroys; the potential treatment is now preparing to move into phase 2 clinical trials. Quantum BioPharma stands among a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, a group that also includes Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol Myers Squibb Company (NYSE: BMY).

Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.

Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy.

When buying international ETFs, owning more stocks in more countries might be a better bet.

The Vanguard Total International Stock ETF's (VXUS) outperformance stems from where it invests.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through

Yesterday's slow-growing economies might be tomorrow's best places to invest.

The most recent research report on the "Dry eye syndrome drugs Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic foreca

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.

This little-discussed pipeline program could prove to be a big success.

A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles.

The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular and retinal disease. Management highlighted phase I clinical results, plans for ne

PTCT Q1 2026 Earnings Transcript

The biotech stock skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.

Incyte (INCY) Q2 2025 Earnings Transcript

Novartis stock fell early Tuesday on lighter-than-expected first-quarter earnings and sales amid U.S. generic erosion.

Both are great stocks to buy in the current environment, but which one is the better bet?